Kyle Bass Group Gets PTAB To Review 2 Celgene Patents
The Patent Trial and Appeal Board on Tuesday agreed to review two more drug patents challenged by hedge fund manager Kyle Bass, finding that his organization has shown that two Celgene...To view the full article, register now.
Already a subscriber? Click here to view full article